Purified protein derivative (PPD) skin testing is used to identify persons infected with Mycobacterium tuberculosis (Mtb) and to assess cell-mediated immune responses to Mtb. However, lack of skin induration to intradermal injection of PPD or PPD anergy is observed in a subset of patients with active tuberculosis (TB). To investigate the sensitivity and persistence of PPD reactivity and its in vitro correlates during active TB disease and after successful chemotherapy, we evaluated the distribution of skin size induration after intradermal injection of PPD among 364 pulmonary TB patients in Cambodia. A subset of 25 pulmonary TB patients who had a positive skin reaction to mumps and͞or candida antigens showed persistent anergy to PPD after successful completion of TB therapy. Strikingly, in vitro stimulation of T cells from persistently anergic TB patients with mumps but not PPD resulted in T cell proliferation, and lower levels of IL-2 and IFN-␥ and higher levels of IL-10 were detected in PPD-stimulated cellular cultures from PPD-anergic as compared with PPD-reactive pulmonary TB patients. These results show that anergy to PPD is antigen-specific and persistent in a subset of immunocompetent pulmonary TB patients and is characterized by antigen-specific impaired T cell proliferative responses and a distinct pattern of cytokine production including reduced levels of IL-2.
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I
t is estimated that one third of the earth's population is infected with Mycobacterium tuberculosis (Mtb), the bacterium that causes tuberculosis (TB; ref. 1) . Infection with Mtb results in a variety of conditions ranging from asymptomatic infection to progressive pulmonary or extrapulmonary TB and death, with approximately 10% of those infected progressing to some form of active disease during their lifetime (2, 3) . TB infection is thus a significant cause of morbidity, claiming the lives of an estimated 1.7 million people globally in the year 2000 (4) .
The majority of individuals infected with Mtb develop a delayed-type hypersensitivity (DTH) response 2 to 4 weeks after infection (5) , which is manifested as a positive response (skin induration) to intradermal injection with purified protein derivative (PPD) derived from Mtb. PPD or tuberculin testing is used to screen for TB infection and guide decisions about chemoprophylaxis and treatment (6) . However, the interpretation of PPD results is affected by the immune status of the individual tested because conditions that interfere with generalized cell-mediated DTH responses including HIV infection, chemotherapy, steroid use, and neoplasia also interfere with reaction to PPD (7) (8) (9) (10) . Interestingly, the absence of skin reactivity to PPD has been described in immunocompetent individuals with active pulmonary TB disease (8, 11) . Recently, we have shown that this anergy is persistent in a certain subset of TB patients who have been successfully cured of TB, where it is associated with IL-10-producing T regulatory (Tr1)-like cells that suppress immune responses to PPD and to nonspecific mitogens in vitro (9) .
To characterize further persistent anergy in vivo in the intact human host and to investigate its in vitro correlates, we investigated the PPD-reactivity of 372 Cambodian TB patients within 2 months of diagnosis and after successful chemotherapeutic cure within the context of a community-based TB treatment program in Svay Rieng Province in the southeast of Cambodia (12) . We note that the country of Cambodia in Southeast Asia is estimated to have the highest prevalence and incidence of TB globally (1) . Strikingly, we found that 37% of acutely ill, HIV-1-negative, pulmonary TB patients had skin indurations of less than 10 mm in response to PPD. Moreover, after successful TB chemotherapy, a subset of 25 of these patients had persistently absent DTH to PPD but detectable DTH responses to candida and mumps antigens.
Consistent with our in vivo findings, our in vitro analyses of T cell responses of persistently PPD-anergic TB patients revealed that although they proliferated in response to mumps, they failed to proliferate in response to PPD. Furthermore, PPDstimulation of peripheral blood mononuclear cells (PBMC) from PPD-anergic patients resulted in less IL-2 production as compared with PBMC from PPD-reactive TB patients. Thus, the absence of DTH to PPD does not exclude a diagnosis of pulmonary TB and, furthermore, it is persistent and antigenspecific in a certain subgroup of immunocompetent TB patients. Moreover, PPD anergy is associated with defective T cell responses including an antigen-specific impaired ability to produce IL-2 and to proliferate in response to PPD challenge.
Methods
Study Site and Subjects. The study subjects were Cambodian patients recruited from the Cambodian Health Committee (CHC) TB treatment program in southeastern rural Cambodia (Svay Rieng Province; ref. 12). The diagnosis of clinical TB was made on the basis of medical history, physical examination, and the detection by light microscopy of acid-fast bacilli (AFB) in sputum, pleural fluid, or lymph node drainage. All patients completed anti-TB chemotherapy according to the protocol of the Cambodian National TB Program: isoniazid͞rifampin͞ pyrazinamide͞ethambutol for 2 months (inpatient phase) and isoniazid͞ethambutol for 6 months (outpatient phase). All patients were tested for clearance of AFB from their sputum at 2, 6, and 8 months after beginning anti-TB therapy.
TB inpatients were screened with PPD within 2 months of diagnosis and initiation of drug therapy in three district hospitals Statistical Analysis. Normally distributed variables were analyzed by the paired t test. Overall frequencies were compared by using a 2 ϫ 2 Fisher exact test. We report levels of significance as P values for all experiments and comparisons. We performed all data analyses with the aid of INSTAT software (GraphPad, San Diego). (Table 1 ). All initial screenings on TB inpatients were performed within 2 months of diagnosis and the initiation of therapy. Of those screened, 364 carried the diagnosis of pulmonary TB with AFB-positive sputum, and 8 individuals had extrapulmonary TB (Table 2) . Of the total 364 pulmonary TB patients who were screened for DTH to PPD, 136 (37%) had induration of less than 10 mm during initial screening; among this group, 69 patients (19%) had no detectable dermal reactivity to PPD (Fig. 1) . Serologic testing to determine whether the absence of DTH response to PPD was caused by HIV-1 infection revealed that four patients who were PPD-anergic upon initial screening were HIV-1 positive (one in January 1999, two in March 2000, and one in March 2001), and they were thus excluded from the study ( Table 1 ). All eight extrapulmonary TB patients displayed a skin reaction of greater than 10 mm. Thus, lack of DTH to PPD or a skin reaction of less than 10 mm is not a useful indicator for ruling out active pulmonary TB. The four initial screenings identified 59 HIV-1-negative individuals who had no induration 48 h after intradermal injection with 5 TU PPD and were thus PPD-anergic (Table 1) . Four of these individuals died of complications from pulmonary TB during therapy and were thus unavailable for PPD rescreening. Of the surviving 55 HIV-1-negative PPD-anergic TB patients identified during the four initial screenings, 26 became PPDϩ upon rescreening after completion of therapy. Follow-up of the , seven anergic patients were identified, one tested positive for HIV-1 infection. Sex-and age-matched PPDϩ patients with TB who were PPDϩ on initial screening remained PPDϩ on subsequent screening (data not shown). We also note that all patients were tested for clearance of AFB from their sputum at 2, 6, and 8 months after beginning anti-TB therapy and there was no statistical difference between the time to AFB clearance between the persistently PPD-anergic patients and the PPDϩ patients (data not shown). PTB, pulmonary TB. remaining 29 anergic individuals revealed that, although they had all been successfully treated and had no clinical evidence of TB, including AFB-negative sputum, they remained anergic to PPD upon rescreening in at least two separate visits ( Table 1) . The six HIV-1-negative PPD-anergic TB patients identified in March 2001 (Table 1) are still under treatment and will be followed up for persistent lack of DTH response to PPD after cure has been achieved. We note that analysis of the baseline characteristics including age, gender, and diagnosis of pulmonary vs. extrapulmonary TB of the PPD-reactive and PPDanergic patients showed no statistically significant differences (Table 2) . Taken together, we conclude that lack of DTH to PPD in the 29 anergic patients identified was not a transient phenomenon associated with active pulmonary TB but was persistent after successful completion of therapy, as documented by AFB-negative sputum and the absence of clinical signs or symptoms of active TB infection.
Results

Identification of PPD-Anergic
Lack of Response to PPD Is Antigen-Specific in Vivo and in Vitro in
Persistently PPD-Anergic TB Patients. To determine whether the lack of DTH to PPD in the cohort of 29 persistently PPD-anergic patients was antigen-specific, we next evaluated their DTH response to other antigens. As shown in Table 3 , 25 of the 29 PPD-anergic individuals had a positive skin reaction to mumps or candida. Four PPD-anergic patients who had no clinical evidence of immunosuppression, and who remained HIV-1-negative on rescreening, also did not react to either mumps or candida (Table 3) , which is consistent with the observation that reactivity to these two antigens in immunocompetent individuals is approximately 50 to 80% and 55 to 75%, respectively (7, 14) . Thus, lack of DTH to PPD is antigen-specific in a certain subset of TB patients and furthermore, a positive response to control antigens is not predictive of a positive response to PPD in immunocompetent Cambodian individuals with active TB. We next isolated CD4 ϩ T cells and autologous APC from TB patients who were anergic to PPD but who had a skin reaction to mumps and from PPDϩ TB patients; we measured T cell proliferation in response to PPD or mumps stimulation in vitro. Strikingly, the proliferative response of T cells from PPD-anergic TB patients to PPD was significantly reduced as compared with the response of T cells from PPDϩ TB patients. By contrast, stimulation of T cells from anergic TB patients with mumps antigen resulted in proliferation, although the response to mumps was slightly lower in the anergic patients (Fig. 2) . We note that we previously demonstrated that APC from PPDanergic and PPD-responsive patients stimulate a mixed lymphocyte reaction equivalently (9) . Here, by demonstrating that T cells from PPD-anergic but mumps-responsive proliferate in response to mumps, we have ruled out defective antigen presentation by APC as the cause of impaired T cell responses to PPD in anergic patients. Taken together, we conclude that the lack of antigen-specific DTH to PPD in vivo observed with skin testing is associated with an ineffective and antigen-specific clonal response of T cells in vitro.
Previously, we reported that T cell receptor (TCR)-mediated stimulation of T cells from PPD-anergic patients resulted in defective phosphorylation of TCR and defective activation of ZAP-70 and MAPK (9), proteins that are critical for IL-2 gene transcription and protein production after antigen stimulation of T cells (15, 16) . Given that the clonal expansion of T cells in response to antigen depends upon IL-2 production, we hypothesized that antigen-specific impairment of IL-2 production may play a role in PPD-anergy. Thus, we next investigated the kinetics of induction of IL-2 in PBMC from PPD-anergic and PPDreactive TB patients after in vitro stimulation with PPD or mumps. As shown in Fig. 3 , IL-2 levels were dramatically increased by PPD in PPD-reactive individuals but only minimally induced in PPD-anergic patients 24 h after stimulation. By contrast, mumps-stimulated IL-2 levels reached similar levels in cells from PPD-reactive and PPD-anergic individuals (Fig. 3) . Thus, the inability of T cells to respond to PPD in vivo as measured by a negative DTH skin reaction in PPD-anergic patients is associated in vitro with lower levels of IL-2.
After 24 h of PPD stimulation, IFN-␥ production also was impaired in response to PPD, and increased levels of IL-10 were detected in cellular culture supernatants from PPD-anergic patients; these differences persisted up to 36 h after stimulation with PPD (Fig. 3) . Notably, the levels of IFN-␥ and IL-10 reached similar levels in mumps-stimulated PBMC from both PPD-reactive and PPD-anergic TB patients (Fig. 3) . Taken together, we conclude that in addition to impaired production of IFN-␥ and higher levels of the immunosuppressive cytokine IL-10, the inability of T cells from PPD-anergic patients to respond to PPD in vivo is associated in vitro with antigen-specific impaired T cell proliferation and production of IL-2.
Discussion
Tuberculin skin testing is the major initial screening method used to diagnose both latent and active TB infection (17) . Notably, more than a third of 364 Cambodian patients with active pulmonary TB had less than a 10 mm intradermal reaction to PPD, and 19% of these patients had no detectable skin reaction. Furthermore, 86% (25͞29) of persistently PPD-anergic Cambodian pulmonary TB patients had a positive skin reaction to intradermal injection of mumps or candida antigens. Taken together, we conclude that negative PPD testing is not a useful indicator for ruling out active pulmonary TB and, therefore, does not obviate the need for further microbiologic or modern nucleic acid testing when there is clinical suspicion of active TB disease.
Furthermore, although positive responses to control antigens are commonly used to rule out generalized anergy and to validate a negative PPD skin test (11, 18) , our results argue against the value of anergy testing with control antigens because responsiveness to other antigens was not predictive of responsiveness to PPD in our cohort (19) (20) (21) .
Previously, we demonstrated that IL-10-producing T cells were constitutively present in the peripheral blood of anergic patients. Furthermore, we showed that T cell proliferation in response to PPD as well as nonspecific mitogens was significantly impaired in anergic patients, and that an anti-IL-10-neutralizing antibody resulted in the restoration of proliferation of these T cells in response to PPD or nonspecific mitogens (9) . Intriguingly, T cell proliferation in response to mumps was only slightly lower than in response to PPD, which is consistent with the hypothesis that PPD and nonspecific mitogens activate an IL-10-producing PPD-responsive T cell clone that is immunosuppressive, whereas the specific mumps antigen does not. The slightly lower T cell proliferation in response to mumps is likely because of the constitutive presence of IL-10-producing T cells (9) . Taken together, we conclude that PPD-anergy can be specifically induced by mycobacterial antigens in vivo in certain Mtb-infected individuals.
Notably, we have shown here that T cells from persistently PPD-anergic patients display an antigen-specific impairment of IL-2 production. Taken together with our previous results demonstrating that T cells from anergic TB patients display defective phosphorylation of TCR and defective activation of Table 3 , of the 29 persistently anergic patients, 13 were reactive to mumps and were persistently not reactive to PPD. Three of these six patients were randomly chosen, and three age-and sex-matched PPD-responsive patients were chosen and studied. The results also are presented as the mean Ϯ SD of experiments from the three different RP and the three different AP pulmonary TB patients (all experiments performed in triplicate). The optimal concentrations of antigen loading of autologous APC (10 g͞ml for PPD or 1 g͞ml for mumps) and time length of culture (5 days) were first established in control experiments with samples from healthy PPDϩ and mumpsϩ volunteer blood donors (data not shown). Results of three representative patients are shown.
ZAP-70 and MAPK proteins (9), we speculate that impaired signaling through the TCR and defective activation of these early intracellular signal events of T cell activation are directly involved in PPD-induced IL-2 gene transcription and subsequent protein production. In addition to impaired IL-2 production, we also have shown here that anergic patients display antigenspecific impaired IFN-␥ production and antigen-specific increased production of IL-10 in response to PPD.
DTH is generated by class II-mediated presentation of antigens to CD4 ϩ T cells and clinical conditions that cause impaired cell-mediated immunity such as AIDS results in impaired DTH responses, negative tuberculin conversion, and an increase in clinical TB in latently infected individuals (7, 18) . Although in animal models, bacillus Calmette-Guérin vaccination of the host results in a reduction of the number of viable mycobacteria in the stationary phase relative to nonvaccinated hosts (22) , a correlation of bacillus CalmetteGuérin vaccination, PPD reactivity, and resistance to TB infection has not been demonstrated in humans (23) . Here, we have characterized a group of individuals who despite active pulmonary TB followed by successful chemotherapeutic cure, display no DTH to PPD. Given that these persistently anergic TB patients have impaired clonal expansion of PPD-specific T cells, compromised production of the effector cytokines IL-2 and IFN-␥, and high levels of the immunosuppressive cytokine IL-10, it seems likely that they are at a disadvantage for clearing Mtb infection and at a higher risk for developing progressive TB disease. In this regard, it is interesting to note that the only four patients among the individuals screened in this study who died of TB disease were anergic to PPD upon initial screening. Moreover, one of the persistently anergic individuals had reported two previous episodes of pulmonary TB, which by history had been adequately treated, which suggests either exogenous reinfection or persistence. Longterm follow up of this cohort of patients will be necessary to determine whether lack of DTH to PPD predisposes individuals to reactivation of persistent organisms or to reinfection (24) . Before effective TB chemotherapy, approximately 50% of those who developed active TB died (25) . Thus, it is interesting to speculate that in the absence of TB treatment, persistently anergic patients would be at a particular disadvantage for containing TB infection and would more often fall into the group that did not survive their TB in the pretreatment era.
Previous studies have suggested that certain populations display greater resistance and that others seem to be at greater risk for both increased susceptibility to infection and progressive disease caused by Mtb. For example, the frequency of protection from TB infection in Caucasians seems to be greater compared with African-Americans (26) . Other studies have demonstrated an association between the HLA class II DR2 serotype with the development of clinical TB in diverse populations including persons from India, Indonesia, Russia, and Mexico (27) (28) (29) (30) . The demonstration in Cambodia of an association between the HLA-DQB1*0503 allele and TB disease progression (31) further supports the contention that genetic factors are involved in susceptibility to developing progressive, clinical TB.
The results presented here that a certain subset of pulmonary TB patients display persistent and PPD-specific anergy strongly suggests that certain individuals have an innate genetic inability to mount an antigen-specific DTH response to PPD. Interestingly, a high incidence of PPD-anergy was demonstrated in Amazonian Yanomami TB patients, where 46% of 26 acutely ill patients had PPD skin reactions less than 10 mm (32). This finding was attributed to the recent exposure of the indigenous Yanomami population to TB infection and thus to the lack of selection pressures favoring the survival of individuals with DTH among the Yanomami population. Thus, in addition to the historical and social realities that exist in Cambodia (12, 33) , it is interesting to speculate that genetic factors may have played a significant role in the severe TB epidemic currently ongoing in Cambodia. It will be of interest, therefore, to determine whether other, distinct ethnic groups have the same rate of persistent anergy among immunocompetent TB patients as we have observed in Cambodia.
Finally, this study demonstrates that community-based TB program design and implementation in an impoverished rural setting of high TB prevalence and incidence where patient follow-up is possible, even years after treatment (12) , provides a model approach for providing basic knowledge about genetic and biochemical factors involved in effective immunity to Mtb. This information could provide a basis for immunotherapeutic approaches including strategies to reverse PPD-anergy that may lead to cure and eradication of TB.
We thank Dr. Fred Rosen for critical research support, Audrey Bernfield for her support, and Dr. William Stead for helpful discussions and Fig. 3 . Kinetics of IL-2, IFN-␥, and IL-10 production in PBMC from anergic and PPDϩ TB patients. PBMC cultures were prepared from PPD-reactive patients (RP) and persistently PPD-anergic patients (AP) and were stimulated with 10 g͞ml of PPD or 1 g͞ml of mumps added directly to the bulk cultures. Supernatants were collected 0, 6, 12, 24, and 36 h later. The levels of IL-2, IFN-␥, and IL-10 at the indicated times were assessed by ELISA. Cytokine levels are depicted as the amount of secreted cytokine in PPDstimulated cultures minus the amount in medium alone. As shown in Table  3 , of the 29 persistently anergic patients, 13 were reactive to mumps and were persistently not reactive to PPD. Four of these six patients were chosen randomly, and four age-and sex-matched PPD-responsive patients were chosen and studied. The results are presented as the mean Ϯ SE of experiments using cells from four different PPD-responding patients (RP) and four different anergic (AP) pulmonary TB patients (all experiments performed in triplicate) at each time point. We note that in previous studies, we detected the constitutive presence of IL-10-producing Tr1-like immunosuppressive T cells and a decreased number of IFN-␥-producing T cells in PBMC from PPD-anergic patients by intracellular cytokine staining (9) . We were unable to detect IL-2-producing T cells by intracellular staining (data not shown). Furthermore, we did not detect IL-4, IL-12, or TGF-␤ protein levels in PBMC stimulated with aqueous sonicate of Mtb (H3Rv7) as measured by ELISA (9) . comments on the manuscript. We also thank Dominique Rousset, Christopher Dascher, Megan Murray, and Shahin Ranjbar for assistance with sample collection in Cambodia. We are deeply indebted to the TB patients in Svay Rieng who generously participated in this study and to the assistance of the Cambodian Health Committee staff, particularly Riel Sarom, without whom this study would not have been possible. This work was supported by National Institutes of Health Grant HL-59838 (to A.E.G. and E.J.Y.), a grant from the American Heart Association (to A.E.G.), and by a Paul Dudley White Traveling Fellowship from Harvard Medical School (to E.Y.T.).
